Northwest Biotherapeutics' brain cancer therapy faces 931-day delay in UK approval

Northwest Biotherapeutics, a public biotech developing a brain cancer treatment, filed a marketing application with the UK Medicines and Healthcare products Regulatory Agency (MHRA) in late December 2023.

The submission was placed on an expedited pathway intended for drugs addressing serious unmet medical needs, with an expected review time of 150 days.

As of July 9, 2026, more than two years and six months (931 days) have passed without an approval decision, marking a far longer timeline than anticipated.

The MHRA has declined to comment on the delay, stating that updates are the responsibility of Northwest Biotherapeutics.